Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
With the development of the first GIP/GLP-1 co-agonist, tirzepatide, there has been an exponential increase in the effectiveness of incretin-mimetic pharmacological therapy for weight control in obese patients with and without diabetes
Naranjo-Galindo FJ, Ai R, Fang EF, Nilsen HL, SenGupta T (2022) C
Evidence Gaps: Most positive findings come from topical formulations or small studies
One in vitro study appears to suggest the half-life of DSIP to be around 15 minutes, while animal studies suggest 4-5 minutes
The blend offers convenience for researchers running protocols that would otherwise require two separate vials
Rare, mild side effects can include temporary redness at the injection site, mild fatigue, or a slight increase in appetite
)
